Prosecution Insights
Last updated: November 04, 2026
Application No. 18/842,601

PASTE COMPOSITION, BIODEGRADABLE INJECTABLE PASTE, AND METHOD FOR PRODUCING SAME

Non-Final OA §103§112
Filed
Apr 04, 2025
Priority
Mar 11, 2022 — RE 10-2022-0030576 +2 more
Examiner
CONIGLIO, AUDREA JUNE BUCKLEY
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Genewel Co. Ltd.
OA Round
1 (Non-Final)
53%
Grant Probability
Moderate
1-2
OA Rounds
1y 8m
Est. Remaining
73%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allowance Rate
458 granted / 864 resolved
-7.0% vs TC avg
Strong +20% interview lift
Without
With
+20.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
46 currently pending
Career history
910
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
51.9%
+11.9% vs TC avg
§102
9.0%
-31.0% vs TC avg
§112
25.9%
-14.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 864 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-18 are pending in the application. Information Disclosure Statement The information disclosure statements (IDS) submitted on 8/29/24; 6/10/25; and 9/24/25 have been considered by the examiner. Priority Receipt is acknowledged of certified copies of papers as filed 8/29/2024 and claiming certified copy of PCT/KR2023/003119, KR 10-2022-0030577 as made available under the PCT and received at the International Bureau. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites as a parenthetical expression “control of water content” as if it is a species of the intended use of “controlled modification” recited in the preamble. It is unclear whether this species recitation is a requirement or a potential recommendation of the claimed controlled modification intended use parameter, and interpretation of the claim language as written may reasonably vary from one artisan to another. Claims 2-17 require all limitations of claim 1. Appropriate clarification is required. In claim 10, there are multiple components recited qualitatively with regard to a weight ratio however only two numbers in a weight ratio such as a range of what may be considered a part and a whole or a numerator and a denominator. How to interpret the ranges and parts/wholes may vary from one artisan to another. Similarly, claim 13 includes a pushing force parenthetical expression which is similarly unclear. Appropriate clarification is required. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-10 and 18 are rejected under 35 U.S.C. 103 as being unpatentable over KR20070046093 (Moller et al., “Moller”, translation enclosed). The pending claims are drawn to a paste composition comprising at least two backbone polymers, a diglycidyl ether monomer, an active ingredient, and a carrier, wherein the at least two backbone polymers, the diglycidyl ether monomer, the active ingredient, or the mixture thereof is uniformly distributed in the carrier, the backbone polymers or the active ingredient includes an adhesive polymer having a single-helix structure to form a scaffold backbone, and the carrier is not reactive with the backbone polymers, the diglycidyl ether monomer, and the active ingredient. The preamble of claim 1 is interpreted as an intended use which does not impart further structural limitations into the claims beyond the structural components otherwise listed and addressed below. Moller teaches a paste which includes gelatin and hyaluronic acid cross-linked with 1,4-butanedioldiglycidyl ether in water wherein hyaluronic acid is added to gelatin to form a sponge having a porous structure (see [0036], [0060], [0078], [0106], [0107], [0161], [0168], and [0186]). Moller’s denatured collagen which is gelatin constitutes one of the at least two backbone polymers and hyaluronic acid the other backbone polymer (see page 4 of 23 of translation, first full paragraph) wherein the denatured collagen is considered a single-helix structure to form a scaffold backbone in accordance with the definitions provided in the instant specification as filed for instance at paragraph [0008] and paragraph [0024](see also limitation of instant claim 5 wherein hyaluronic acid and/or gelatin may be considered also as active ingredients). Moller further includes 1,4-butanedioldiglycidyl ether as a chemical crosslinker (see page7 of 23 of translation, first paragraph line 3)(“a diglycidyl ether monomer” as in claim 1). Moller teaches saline as a most preferred solvent which may be considered a carrier of the paste formulation (see page 7 of 23 of translation, paragraph starting “The paste may be obtained by suspending particles…”), and this portion of Moller generally describes suspension of a stabilized paste formulation which appears to describe a uniform distribution in a carrier, as recited further in claim 1 and wherein the carrier would not be considered reactive with backbone polymers or additional claimed components as also further recited in claim 1. Moller teaches that the formulations may include active agents such as thrombin-stabilizing agents or for instance an active agent which is aprotinin or pepstatin or fibronectin or tranexamic acid for instance (see claim 7). Because Moller does not teach a single embodiment necessarily including the requisite components claimed, this rejection is made using obviousness rationale. It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was filed to combine the aforementioned elements in a single product or in a single process of making a hemostatic sponge surface as taught by Moller, with a reasonable expectation of success. One would have been motivated to do so where Moller teaches structural and functional advantages of each formulation component as addressed above, and one reasonably would have expected success from combining these known elements into a single embodiment of the invention for hemostatic functionality in medical applications. Regarding claim 3, Moller teaches that collagen denatured results in gelatin which may be used as the gelatin component (see page 4 of 23, first full paragraph of translation). Regarding claim 4, Moller suggests that the hyaluronic acid may be added to gelatin to form a sponge with the hyaluronic acid bound to the inside of the sponge and uniformly located inside a reticulate sponge structure (see [0060] and [0186]), which appears to be a structure the same or substantially the same as instantly claimed. Regarding claims 6 and 9, Moller teaches hyaluronic acid and water (see [0106]). Regarding claim 7, Moller teaches cellulose components including carboxymethylcellulose in addition to the aforementioned gelatin and collagen components (see “The biologically absorbable material…” paragraph of translation). Regarding claim 8, Moller teaches that surfactants including starches may be included (see “Examples of nonionic surfactants” paragraph of translation). Regarding claims 2 and 10, Moller appears to teach the same or substantially the same components to be used in a product for the very same purpose, however Moller does not recite an amount of carrier as a weight percentage or weight ratios of formulation components as in the respective claims. Accordingly, as to the absolute and/or relative amounts which may be expressed as weight ratios, it is the examiner’s position that it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was filed to perform routine optimization procedures with regard to the amounts, parts and wholes, to achieve the desired end result such as adhesive efficacy and total formulation hemostatic effect and stability, as is customary in the art. One would have been motivated to do so as part of routine inquiry to maximize stability and benefits and minimize undesired physical properties for instance. Regarding claim 18, Moller teaches a method for preparing a paste by including hyaluronic acid solution with a sponge having a porous structure and performing crosslinkage and subsequent wetting the sponge in a saline solution to make a paste, steps which appear to achieve a base formulation, a porous scaffold, and obtaining a biodegradable injectable paste the same or substantially the same as claimed, absent evidence to the contrary. Moller teaches the sponge may be mixed, dried by heating, and sterilized as well as subsequent grinding into powder or flakes for instance by milling, extrusion, granulation, or similar (see page 7 of 23 of translation, in particular). Claims 11-17 are rejected under 35 U.S.C. 103 as being unpatentable over KR20070046093 (Moller et al., “Moller”, translation enclosed) as applied to claims 1-10 and 18 above, and further in view of KR20130123080A (Lee et al., hereafter “Lee”, translation enclosed). The teachings of Moller as they pertain to claims 1-10 and 18 have been delineated above. Further regarding claim 11, Moller does not specify the paste to include micro-hydrogel particles including the components otherwise addressed above and having the characteristics and/or characteristic functions and intended processes of use further recited in claim 11 (“that maintiains a balance between viscosity and elasticity by including…” and “exhibits a paste form that is applicable to an application site using one syringe by comprising the carrier in an amount…”). It is noted that Moller teaches injection (“In addition to the above test method,” paragraph of translation) thereby suggesting Moller’s paste is injectable. As to the claim language “obtained from” and “offers a form…” and “exhibits a paste form that is applicable…”, these functions appear inseparable from the structural components addressed above in regard to claim 1 and to be used for the very same purpose. As to the micro-hydrogel particles recited in claim 11 and the specific size recited in claims 12 and 13, Lee cures this deficiency. Like Moller, Lee teaches crosslinked hyaluronic acid materials and process of making these for application to biological tissue (see abstract, in particular). Lee’s Example 1 teaches pulverization of the washed hyaluronic acid crosslinked material to a particle size of 100 to 500 micrometers (see translation of Example 1), a range entirely included by the range recited in claims 12 and 13. As to the tack value recited in claim 14, the water content character recited in claim 15, the blood coagulation index in claim 16, and the viscosity character in claim 17, Lee teaches the tack as a function of concentration of hyaluronic acid crosslinked as measured using a rheometer (see Example 2, Figure 2, and Test Example 2). Where, as here, the claimed and prior art products are identical or substantially identical, or are produced by identical or substantially identical processes, the PTO can require an Applicant to prove that the prior art products do not necessarily or inherently possess the characteristics of his claimed product. See In re Ludtke, 441 F.2d 660, 169 USPQ 563 (CCPA 1971). Whether the rejection is based on "inherency" under 35 USC 102, on "prima facie obviousness" under 35 USC 103, jointly or alternatively, the burden of proof is the same, and its fairness is evidenced by the PTO's inability to manufacture products or to obtain and compare prior art products. In re Best, Bolton, and Shaw, 195 USPQ 430, 433 (CCPA 1977) citing In re Brown, 59 CCPA 1036, 459 F.2d 531, 173 USPQ 685 (1972). In the instant case, it is the examiner’s position that the tack value claimed in claim 14 appears to be the same or substantially the same as would have resulted from the combination of Moller and Lee teachings to be used for the very same purpose. Similarly, the water content and blood coagulation index properties described in claims 15 and 16 as well as the viscosity further detailed in Lee’s Test Example 1 complex viscosity measurement methods of analysis appear to be the same or substantially the same as would have resulted from the combination of Moller’s hemostatic material with Lee’s hyaluronic acid tissue adhesion material, absent evidence to the contrary. Both Moller and Lee pertain to functional hyaluronic acid or similar materials for topical application in hemostatic and/or wound treating type applications. It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was filed to combine the elements outlined above wherein the particles are in the form of a micro-scale hydrogel material, as suggested by Lee using the components of Moller, with a reasonable expectation of success. One would have been motivated to do so to facilitate good formulation of usable products with a stable physical formulation as suggested by Lee. Further, one would have been motivated to measure and/or optimize additional parameters including particle size, particle diameter pushing force, tack force, water content, blood coagulation index, and viscosity so to achieve the desired end result for instance as a function of hyaluronic acid or equivalent concentration as reasonably suggested by the teachings of Moller and Lee considered as a whole by the ordinary artisan. One would have been motivated to do so to facilitate good physical stability for story and for use as a hemostatic and/or topical or injectable formulation in accordance with the teachings of Moller and Lee. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to AUDREA B CONIGLIO whose telephone number is (571)270-1336. The examiner can normally be reached Monday - Thursday 7:00 a.m. - 5:30 p.m.. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 5712720616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AUDREA B CONIGLIO/Primary Examiner, Art Unit 1617
Read full office action

Prosecution Timeline

Apr 04, 2025
Application Filed
Oct 28, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778119
ANTIMICROBIAL POLYMERIC COMPOSITION
3y 2m to grant Granted Nov 03, 2026
Patent 12773252
COSMETIC COMPOSITION INTENDED FOR THE TREATMENT OF SKIN HYPERPIGMENTATION AND TREATMENT METHOD USING SAID COMPOSITION
3y 1m to grant Granted Oct 27, 2026
Patent 12758480
PARTICULATE SILICA SILYLATE KIT FOR TREATMENT OF SURFACES FOR HYDROPHOBICITY CHARACTERISTICS
3y 1m to grant Granted Oct 13, 2026
Patent 12740927
MIXED SURFACTANT FOR PREPARING TRANSPARENT MICROEMULSION AND FINE NANOEMULSION, AND COSMETIC COMPOSITION PREPARED USING THE SAME
2y 6m to grant Granted Sep 22, 2026
Patent 12714658
OIL-IN-WATER EMULSIFIED COSMETIC
4y 2m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
53%
Grant Probability
73%
With Interview (+20.2%)
3y 3m (~1y 8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 864 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month